R
RTW Investments, LP
+ を保有ZLAB
-11.48%
3か月リターン
$22.500
-0.585 (-2.60%)終値時点
Loading chart…
- 高値
- 22.800
- 始値
- 22.300
- 出来高加重平均価格
- 22.47
- 出来高
- 849.72K
- 時価総額
- 1.73B
- 安値
- 22.120
- 売買代金
- 19.10M
- EV/EBITDA（TTM）
- -5.92
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
AI分析 of Zai Lab Ltd (ZLAB)
中立Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
アナリスト評価（3）
上値余地 +113.02%
買い
2 買い
1 中立
0 売り
現在: 22.50
安値
25.70
平均
47.93
高値
74.00
JPMorgan
オーバーウェイト
$36
2026-08-27
JPMorgan
2026-08-27
目標株価
$36
オーバーウェイト
Citi
買い
$45
2026-08-07
Citi
2026-08-07
目標株価
$45
買い
Citi
買い
$44
2026-05-08
Citi
2026-05-08
目標株価
$44
買い
JPMorgan
オーバーウェイト
$32
2026-03-18
JPMorgan
2026-03-18
目標株価
$32
オーバーウェイト
Cantor Fitzgerald
オーバーウェイト
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
目標株価
$37
オーバーウェイト
バリュエーション指標
Zai Lab Ltd（ZLAB）の現在の予想PERは0.00で、5年平均は-16.19です。
ZLAB を保有するクジラ
イベントタイムライン
ニュース
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
ZLAB のよくある質問 — Alphio AI が回答
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。